524774 Stock Overview
NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for use in veterinary and human health worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
NGL Fine-Chem Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹2,542.60 |
| 52 Week High | ₹2,688.00 |
| 52 Week Low | ₹1,293.65 |
| Beta | 1.01 |
| 1 Month Change | 25.54% |
| 3 Month Change | 29.72% |
| 1 Year Change | 88.91% |
| 3 Year Change | 54.27% |
| 5 Year Change | 468.56% |
| Change since IPO | 9,387.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| 524774 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 14.0% | -2.5% | -2.5% |
| 1Y | 88.9% | 55.2% | 44.5% |
Return vs Industry: 524774 exceeded the Indian Pharmaceuticals industry which returned 55.3% over the past year.
Return vs Market: 524774 exceeded the Indian Market which returned 45.3% over the past year.
Price Volatility
| 524774 volatility | |
|---|---|
| 524774 Average Weekly Movement | 7.1% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.3% |
Stable Share Price: 524774's share price has been volatile over the past 3 months.
Volatility Over Time: 524774's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 396 | Rahul Nachane | www.nglfinechem.com |
NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for use in veterinary and human health worldwide. It offers active pharmaceutical ingredients, such as diminazene aceturate, diminazene diaceturate, homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, ractopamine HCl, S-methoprene, praziquantel, toltrazuril, decoquinate, flunixin meglumine, carprofen, fenbendazole, amitraz, xylazine hydrochloride, and marbofloxacin for animal health applications; and nitazoxanide and atovaquone for human health applications. The company provides various intermediate products and specialty chemicals; and finished dosage forms in granules and tablets.
NGL Fine-Chem Limited Fundamentals Summary
| 524774 fundamental statistics | |
|---|---|
| Market cap | ₹15.71b |
| Earnings (TTM) | ₹380.04m |
| Revenue (TTM) | ₹3.17b |
41.3x
P/E Ratio5.0x
P/S RatioIs 524774 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 524774 income statement (TTM) | |
|---|---|
| Revenue | ₹3.17b |
| Cost of Revenue | ₹1.55b |
| Gross Profit | ₹1.62b |
| Other Expenses | ₹1.24b |
| Earnings | ₹380.04m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 61.51 |
| Gross Margin | 51.24% |
| Net Profit Margin | 11.99% |
| Debt/Equity Ratio | 11.3% |
How did 524774 perform over the long term?
See historical performance and comparison